一项关于咀嚼特鲁瓦达用于暴露前预防（PrEP）并通过一种新型尿液替诺福韦检测法测量维持药物保护水平的案例研究。
A case study of chewed Truvada for PrEP maintaining protective drug levels as measured by a novel urine tenofovir assay.
作者信息
Lalley-Chareczko Linden, Clark Devon, Zuppa Athena F, Moorthy Ganesh, Conyngham Caitlin, Mounzer Karam, Koenig Helen
机构信息
Philadelphia FIGHT Community Health Centers, Philadelphia, PA, USA.
Division of Pediatric Critical Care Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
出版信息
Antivir Ther. 2017;22(7):639-641. doi: 10.3851/IMP3151. Epub 2017 Mar 6.
Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF; Truvada) given as pre-exposure prophylaxis (PrEP) successfully blocks HIV when taken once daily prior to potential HIV exposure. A 22-year-old male reported difficulty swallowing FTC/TDF for PrEP and subsequently began chewing the FTC/TDF tablets. Monthly urine samples assessed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) indicated tenofovir levels >1,000 ng/ml, indicative of protection from HIV acquisition, over a 48-week period. Data from observational studies of HIV-positive patients details the successful treatment of HIV using crushed FTC/TDF delivered via feeding and gastronomy tubes while small, randomized trials of healthy volunteers demonstrate bioequivalence between whole and crushed FTC/TDF.
恩曲他滨/富马酸替诺福韦二吡呋酯（FTC/TDF；特鲁瓦达）作为暴露前预防（PrEP）药物，在潜在HIV暴露前每日服用一次时可成功阻断HIV。一名22岁男性报告称吞咽用于PrEP的FTC/TDF有困难，随后开始咀嚼FTC/TDF片剂。使用液相色谱-串联质谱法（LC-MS/MS）评估的每月尿液样本显示，在48周期间，替诺福韦水平>1000 ng/ml，表明可预防HIV感染。对HIV阳性患者的观察性研究数据详细说明了通过喂养管和胃造瘘管给予碾碎的FTC/TDF成功治疗HIV的情况，而针对健康志愿者的小型随机试验表明完整的和碾碎的FTC/TDF具有生物等效性。
Zotero 插件